Analyst Reco. Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-02 EDT			5-day change	1st Jan Change
7.29 ^USD	+1.11%		+17.20%	+231.36%

04-01	ADRs End Higher; Connect Biopharma Climbs 26%	DJ
03-28	ADRs End Lower; NuCana Slides 15%	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fed Rate Outlook Weakens Exchange-Traded Funds, Equity Futures Premarket Thursday	23-09-21	MT
Cantor Fitzgerald Adjusts Price Target on Mesoblast to $17 From $23, Maintains Overweight Rating	23-08-31	MT
Maxim Downgrades Mesoblast to Hold From Buy	23-08-07	MT
Piper Sandler Downgrades Mesoblast to Neutral From Overweight, Adjusts Price Target to $2 From $7	23-08-04	MT
William Blair Downgrades Mesoblast to Market Perform From Outperform	23-08-04	MT
Chardan Trims Price Target on Mesoblast to $1.50 From $2, Maintains Sell Rating	23-08-04	MT
Chardan Cuts Price Target on Mesoblast to $2 From $2.50 Reflecting Increased Share Count Dilution, Reiterates Sell Rating	23-05-30	MT
Cantor Fitzgerald Reiterates Mesoblast at Overweight With $23 Price Target	23-02-01	MT
Jefferies Downgrades Mesoblast to Hold From Buy	22-12-06	MT
Piper Sandler Starts Mesoblast at Overweight With $7 Price Target	22-09-06	MT
Chardan Lowers Mesoblast's Price Target to $2.50 From $6.50, Maintains Sell Rating	22-06-03	MT
MESOBLAST : Jefferies Downgrades Mesoblast to Hold From Buy	21-08-31	MT
MESOBLAST : Chardan Adjusts Mesoblast's Price Target to $6.50 From $7.50, Maintains Sell Rating	21-08-31	MT
Mesoblast : COVID-19 Drug Remestemcel-L's ARDS Trial Enhances Survival Rate in Patients	21-07-19	MT
MESOBLAST : Maxim Group Upgrades Mesoblast to Buy From Hold, Sets $18 Price Target	21-04-07	MT
MESOBLAST : Jefferies & Co Downgrades Mesoblast to Hold From Buy	21-01-19	MT
MESOBLAST : Maxim Downgrades Mesoblast to Hold From Buy	20-12-22	MT
MESOBLAST : RBC Capital Adjusts Mesoblast's Price Target to $11 From $12, Maintains Sector Perform-Speculative Risk Rating	20-12-15	MT
MESOBLAST : Chardan Downgrades Mesoblast to Sell From Neutral, Adjusts Price Target to $7.50 From $5.50	20-12-04	MT
MESOBLAST : HC Wainwright Adjusts Mesoblast's Price Target to $20 from $19, Keeps Buy Rating	20-11-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Analyst Reco.

Filters